Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects

NCT02259595 is registered in ClinicalTrials.gov with Otologic Pharmaceutics, Inc. as lead sponsor.

NCT NCT02259595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02259595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects
Lead sponsor
Otologic Pharmaceutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
February 28, 2015
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hearing loss, noise-induced hearing loss, sensorineural hearing loss